EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Clinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study

Rebecca Butfield, Kiran K Rai, Thomas Jennison, Jack Said, Hannah Wright, Dheeraj Sethi, Jonathan Watkins, Antonia Geneidat, Isabel Jimenez, Dexter Wiseman

Infectious Diseases and Therapy · 2026-12 · 15 (12) · 3411-3430

DOI: 10.1007/s40121-026-01447-9 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Infectious Diseases and Therapy, online erschienen am 06.10.2026. Verfasst von Rebecca Butfield und 9 weiteren Autor:innen. Beteiligte Einrichtung: Access & Value, Pfizer Ltd, Tadworth, UK. rebecca.butfield@pfizer.com. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Respiratory syncytial virus (RSV) causes significant disease in older and comorbid adults. Current UK vaccination recommendations restrict eligibility to adults ≥ 75 years, 65-74 years with chronic respiratory disease or immunosuppression, and those in care homes, but evidence on clinical burden in adults < 75 years with comorbidities is limited. This study assessed patient characteristics, healthcare resource utilization (HCRU), and mortality in adults hospitalized with RSV in England. METHODS: Population-based retrospective cohort study using linked Clinical Practice Research Datalink Aurum and Hospital Episode Statistics. Adults ≥ 60 years hospitalized with RSV between October 2014 and March 2019 were included. We defined RSV episodes as 90 days post-diagnosis. We defined cases using diagnosis codes for confirmed RSV (RSV-specific) or acute lower respiratory tract infection with exclusion of other causative pathogens (RSV-possible). All-cause HCRU (hospitalizations, critical care admissions, outpatient attendance, primary care consultations, and prescriptions) and case fatality rates were assessed. Results were stratified by age (60-74 and ≥ 75 years), case definitions (RSV-specific, RSV-possible), and comorbidity profiles (chronic respiratory disease, immunocompromised, cardiovascular disease). RESULTS: A total of 97,712 hospitalized episodes in those aged ≥ 60 years were included in the analysis, of which 785 (0.8%) were RSV-specific cases (n = 338 aged 60-74 years, n = 447 aged ≥ 75 years). In RSV-specific cases, median (IQR) cumulative length of stay (LoS) for those ≥ 75 years was 10.00 (6.00-22.00) days, which was equivalent to or lower than each comorbidity subgroup in those aged 60-74 years, with the longest LoS in those immunocompromised (11.50 [7.00-26.00] days). Critical care admissions were more often observed across comorbidity stratifications (13.85-22.34%) compared to those ≥ 75 years (5.03%). All-cause and RSV-related case fatality rates for RSV-specific cases were highest among those ≥ 75 years (all-cause: 19.3%; RSV-related: 10.3%). CONCLUSIONS: HCRU within RSV episodes in those aged 60-74 years across comorbidity profiles was equal to or greater than that in those aged ≥ 75 years. These findings highlight the need to prioritize consideration of comorbidity groups that could benefit from RSV vaccination.

Schlagwörter

Stichwörter der Autor:innen

AsthmaCardiovascular diseaseChronic kidney diseaseChronic obstructive pulmonary diseaseDiabetes mellitusHealthcare resource utilizationImmunocompromisedRespiratory syncytial virusVaccine

Autor:innen und Institutionen

  • Access & Value, Pfizer Ltd, Tadworth, UK. rebecca.butfield@pfizer.com.
  • Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK.
  • Access & Value, Pfizer Ltd, Tadworth, UK.
  • National Heart and Lung Institute, Imperial College London, London, UK.
  • Chelsea and Westminster National Health Service Foundation Trust, London, UK.

Förderung

  • Pfizer UK

Zitieren

APA

Butfield, R., Rai, K. K., Jennison, T., Said, J., Wright, H., Sethi, D., Watkins, J., Geneidat, A., Jimenez, I., & Wiseman, D. (2026). Clinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study. Infectious Diseases and Therapy, 15(12), 3411-3430. https://doi.org/10.1007/s40121-026-01447-9

Vancouver

Butfield R, Rai KK, Jennison T, Said J, Wright H, Sethi D, et al. Clinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study. Infectious Diseases and Therapy. 2026;15(12):3411-3430. doi:10.1007/s40121-026-01447-9

BibTeX
@article{Butfield2026,
  author = {Butfield, Rebecca and Rai, Kiran K and Jennison, Thomas and Said, Jack and Wright, Hannah and Sethi, Dheeraj and Watkins, Jonathan and Geneidat, Antonia and Jimenez, Isabel and Wiseman, Dexter},
  title = {Clinical Burden of Disease and Demographics in Older Adults Hospitalized with RSV Infection in England: A Retrospective Cohort Study},
  journal = {Infectious Diseases and Therapy},
  year = {2026},
  volume = {15},
  number = {12},
  pages = {3411--3430},
  doi = {10.1007/s40121-026-01447-9}
}
Kostenlos starten →